Usage Examples
- The CCS was rewritten after the Annex 1 gap assessment flagged manual lyophilizer loading.
- Grade A conditions were held from filling through capping, with continuous viable and total particle monitoring.
- One contaminated media fill unit is a failed APS under Annex 1, so every batch since the last successful run is in scope.
What is Annex 1?
Annex 1 is the European Union GMP guideline governing the manufacture of sterile medicinal products, distinguished from other GMP annexes by mandating a facility-wide Contamination Control Strategy and graded cleanroom control, in force since 25 August 2023.
Annex 1 exists because sterility cannot be tested into a product. Annex 1 states that monitoring or testing alone does not give assurance of sterility, and that sole reliance should not be placed on any terminal process or finished product test. Annex 1 therefore regulates the design, qualification and control of the facility, equipment and process that produce the sterile unit.
Annex 1 covers all sterile product types, including active substances, excipients, primary packaging and finished dosage forms, across both terminal sterilisation and aseptic processing. Annex 1 stops at sterility assurance; it is not a full GMP code, and the Chapter 1 pharmaceutical quality system duties still apply on top of it. Annex 1 principles may be voluntarily extended to non-sterile products such as creams and low-bioburden biological intermediates, but that election must be documented.
Annex 1 is applied through the Contamination Control Strategy, the document that ties premises, utilities, personnel, vendor approval, validation and monitoring into one assessed system. In practice, teams map every critical control point into the CCS, classify cleanrooms as grade A, B, C or D, run aseptic process simulations twice a year for each filling line and each shift, and defend that whole chain at inspection.
Not to be confused with
- EU GMP Chapter 1
- Chapter 1 sets the pharmaceutical quality system requirements for every medicinal product. Annex 1 states its sterile-specific duties are in addition to Chapter 1, so satisfying one does not satisfy the other.
- ICH E6(R3) Annex 1
- a Good Clinical Practice annex on the conduct of clinical trials, not manufacturing. The two documents share a number and nothing else; "Annex 1 compliance" is meaningless until you name the parent guideline.
- PIC/S Annex 1
- identical text bar minor editorial differences, same 25 August 2023 date, but it binds through PIC/S member inspectorates rather than the EU Directives. Same expectations, different legal hook.
- Cleanroom classification
- classification proves a room meets particle limits at a point in time. Annex 1 grades add viable action limits (no growth in grade A), continuous grade A particle monitoring for the full duration of critical processing, and gowning duties. A classified room is not a compliant one.
Annex 1 uses "should" throughout, but its scope section states that where specific limits, frequencies or ranges are given, they are a minimum requirement.
What you must do
- 1Implement a Contamination Control Strategy across the facility that defines every critical control point and assesses the effectiveness of all design, procedural, technical and organisational controls, and put its effectiveness into periodic management reviewEU GMP Annex 1 §2.3
- 2Qualify and operate cleanrooms in the four grades, reserving grade A for critical zones such as the filling zone, stopper bowl, open primary packaging and aseptic connections made under first airEU GMP Annex 1 §4.4
- 3Terminally sterilise finished product wherever possible, and where the product cannot tolerate it, document the justification and consider post-aseptic terminal heat treatmentEU GMP Annex 1 §8.34
- 4Treat any contaminated unit in an aseptic process simulation as a failed APS: investigate root cause, implement corrective measures, run normally three consecutive successful repeat APS, and review every batch produced since the last successful APSEU GMP Annex 1 §9.46
- 5Apply the revised text from 25 August 2023, with point 8.123 on lyophilizer loading, unloading and sterilisation frequency applying from 25 August 2024EU GMP Annex 1, Deadline for coming into operation
Common mistakes
Producing a CCS binder for the deadline and never revisiting it
Paragraph 2.3 requires the CCS to be actively reviewed, updated, to drive continual improvement of manufacturing and control methods, and to form part of periodic management review. A CCS that has not changed since the 2023 deadline is evidence the strategy is not running.
Choosing aseptic processing without documenting why terminal sterilisation was rejected
Paragraph 8.34 makes terminal sterilisation the default because it gives greater sterility assurance than sterile filtration or aseptic processing. If neither the CCS nor the dossier records why the product cannot tolerate it, the question arrives at inspection and again during MAA assessment.
Treating one contaminated media fill unit as a minor excursion
Under paragraph 9.46 the target is zero growth and a single contaminated unit is a failed APS. The consequences are a root-cause investigation, corrective measures, normally three consecutive successful repeat runs, and a risk assessment of every batch made since the last successful APS, including batches not yet released to market.
When This Matters
- The CCS was rewritten after the Annex 1 gap assessment flagged manual lyophilizer loading.
- Grade A conditions were held from filling through capping, with continuous viable and total particle monitoring.
- One contaminated media fill unit is a failed APS under Annex 1, so every batch since the last successful run is in scope.
Frequently Asked Questions
Annex 1 applies to any site manufacturing sterile products for the EU market, wherever that site is located. PIC/S adopted an identical text with minor editorial differences on the same date, so most inspectorates outside the EU now assess sterile sites against the same expectations.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- CMC Workflows
Track ICH quality guidelines automatically and get alerts when changes impact your products
- Quality/QA Workflows
Track GxP regulation changes and enforcement trends
